Company Overview

Regeneron Pharmaceuticals, Inc. is a leading American biotechnology company founded in 1988 and headquartered in Westchester County, New York. The company discovers, invents, develops, manufactures, and commercializes medicines for treating a wide range of diseases globally. As of September 24, 2025, Regeneron has a substantial market capitalization of $63.13 billion and employs approximately 15,110 people.

Core Business & Product Portfolio

The company's primary focus is on developing innovative therapies for patients with serious medical conditions. Regeneron's extensive product portfolio includes treatments for eye diseases, allergic and inflammatory conditions, cancer, cardiovascular and metabolic diseases, infectious diseases, and rare diseases.

Flagship Products and Key Offerings

- EYLEA® (aflibercept) injection: A leading treatment for wet age-related macular degeneration (AMD), diabetic macular edema (DME), and other serious eye conditions. Global sales in 2024 were just under $10 billion, with an expected shift to the long-acting Eylea HD formulation.

- Dupixent® (dupilumab) injection: A treatment for moderate-to-severe atopic dermatitis and asthma in adults and pediatrics. Its global net sales in Q1 2025 increased by 19% year-over-year.

- Libtayo® (cemiplimab-rwwh) injection: Used to treat metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) and non-small cell lung cancer.

- Praluent® (alirocumab) injection: For patients with heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease.

- REGEN-COV® (casirivimab and imdevimab) injection: An antibody cocktail for the treatment of COVID-19.

- Kevzara® (sarilumab) injection: An antibody that inhibits interleukin-6 (IL-6) signaling for treating rheumatoid arthritis in adults.

Regeneron also offers Inmazeb™ injection (for Zaire ebolavirus), ARCALYST® injection (for cryopyrin-associated periodic syndromes), ZALTRAP® injection (for metastatic colorectal cancer), Evkeeza® (evinacumab-dgnb) for HoFH, Ordspono™ (pralsetinib) for certain cancers, and Veopoz™ (pozelimab-bbfg) for CD55-deficient protein-losing enteropathy.

Research & Development Pipeline

Regeneron maintains a robust pipeline with approximately 45 product candidates in various stages of clinical development. The company continues to investigate additional indications for its existing marketed products. Its R&D efforts span a broad range of therapeutic areas, aiming to address unmet medical needs across eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases, as well as cancer, pain, and hematologic conditions.

Financial Performance

Recent Financial Results

- 2024 Full Year Performance:

- Revenue: $14.20 billion (an increase of 8.27% from $13.12 billion in 2023)

- Earnings: $4.41 billion (an increase of 11.61% from 2023)

- Q1 2025 Results:

- Revenues of $3.0 billion.

- GAAP diluted EPS of $7.27 and non-GAAP diluted EPS of $8.22.

- Dupixent global net sales reached $3.67 billion, a 19% increase compared to Q1 2024.

- Q2 2025 Performance:

- Reported 4% revenue growth and 12% non-GAAP earnings growth.

- Returned over $2.3 billion to shareholders via share repurchases and dividends since the start of 2025.

Dividend & Shareholder Returns

Regeneron initiated a quarterly cash dividend program in February 2025, declaring an initial dividend of $0.88 per share. The company intends to pay cash dividends on a quarterly basis going forward. As of recent data, the Dividend Yield (TTM) stands at 0.44%.

The company has also increased its share repurchase authorization to approximately $4.5 billion, allowing for flexibility in repurchasing shares.

Strategic Collaborations

Regeneron actively engages in strategic collaborations to advance its research and commercialization efforts:

- Mammoth Biosciences, Inc.: Collaboration to research, develop, and commercialize in vivo CRISPR-based gene editing therapies.

- Sonoma Biotherapeutics, Inc.: Partnership focused on discovering, developing, and commercializing engineered regulatory T cell therapies.

- Sanofi: A significant and long-standing partnership for the commercialization of key products, including Dupixent and Kevzara.

Recent Clinical Developments

Regeneron continues to achieve significant milestones in its clinical development programs:

- Dupixent®: Continues its leadership in type 2 inflammation-driven diseases, gaining recent FDA approvals for bullous pemphigoid and chronic spontaneous urticaria, bringing its total approved indications to eight.

- Oncology Portfolio: Significant progress has been made, including FDA approval for Lynozyfic™ (rebazumab-agf) for relapsed or refractory multiple myeloma. Emerging data from pivotal programs in myeloma and lymphoma, along with positive pivotal data for Libtayo® in adjuvant CSCC, support potential upcoming FDA approvals.

Stock Performance

- All-Time High: $1,211.20 on August 27, 2024.

- All-Time Low: $3.00 on December 29, 1994.

- Beta Coefficient: 0.75.

- Volatility: 5.35%.

Regeneron Pharmaceuticals represents one of the most established and innovative biotechnology companies. With a diversified portfolio of commercialized medicines and a robust pipeline targeting multiple therapeutic areas, the company is well-positioned as a leader in the biopharmaceutical industry.